Tetra Bio-Pharma (TBP.T) announced that their new investigation new drug (IND) ARDS-003 has been studied in a viral infected organoid model as part of a research collaboration between Targeted Pharmaceuticals…
Biotech
Core One Labs’ (COOL.C) wholly-owned subsidiary, Akome Biotech, has begun the development of a next-generation psychedelic drug formulation for the purpose of mitigating neurological damage that results from ischemic…
Enochian BioSciences (ENOB.Q) announced today that the Company has acquired an exclusive license for an innovative technology to potentially treat and prevent all variants of coronavirus, including the cause…
Steady as she goes It’s been a rough couple of quarters for the psychedelics sector at large. Some companies have been able to avoid the correction, but for the…
23andMe Holdings (ME.Q), the California-based personal genomics and biotechnology company, made headlines on Thursday after announcing that it has begun trading on the NASDAQ through an SPAC, sponsored by…
Rollbacks Yesterday Core One Labs (COOL.C) announced an 8:1 share rollback to prepare itself for a Nasdaq listing. Today the company has 114,600,611 common shares outstanding, after the rollback,…
Mind Medicine (MNMD.Q) announced the addition of Dr. Peter Bergethon to their Scientific Advisory Board. Bergethon is a “world-leading” expert in neurology, digital medicine, and central nervous system (CNS)…
MYND Life Sciences (MYND.C) announced they have signed a Letter of Intent (LOI) with Eyam Vaccines and Immunotherapies which outlines an Exclusive Licensing Agreement with respect to Eyam’s proprietary…
Atai is already a whale Although private, no shroom stock discussion is complete without mentioning Berlin-based Atai Life Sciences. The company has remained private since its inception in…
In the biotech/medtech world, the steps to viability as a company are proving your technology works, getting that technology approved by the FDA, finding doctors who are interested in…